Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer in 185 countries. CA Cancer J Clin. 2018. DOI:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yang W, Huang Y, et al. Evolving roles for targeting CTLA-4 in cancer immunotherapy. Cell Physiol Biochem. 2018;47(2):721–734.
   PubMed Web of Science ®Google Scholar
• Callea M, Pedica F, Doglioni C. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cacer immunotherapy and chellenges for the pathologist: state of the art. Pathologica. 2016;108(2):48–58.
   PubMed Web of Science ®Google Scholar
• Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66(5):551–564.
   PubMed Web of Science ®Google Scholar
• Du W, Yang M, Turner A. TIM-3 as a target for cancer immunotherapy and mechanisms of action. Int J Mol Sci. 2017;18(3):E645.
   PubMed Web of Science ®Google Scholar
• Liu LL, Pfefferle A, Yi Sheng VO. Harnessing adaptive natural killer cells in cancer immunotherapy. Mol Oncol. 2015;9(10):1904–1917.
   PubMed Web of Science ®Google Scholar
• Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39–48.
   PubMed Web of Science ®Google Scholar
• Dougall WC, Kurtules S, Smyth MJ, et al. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276(1):112–120.
   PubMed Web of Science ®Google Scholar
• He Y, Rivard CJ, Rozeboom L, et al. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. 2016;107(9):1193–1197.
   PubMed Web of Science ®Google Scholar
• Burugu S, Gao D, Leung S, et al. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol. 2017;28(12):2977–2984.
   PubMed Web of Science ®Google Scholar
• Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171(5):1393–1405.
   PubMed Web of Science ®Google Scholar
• Kisielow M, Kisielow J, Capoferri-Sollami G, et al. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells 2. Eur J Immunol. 2005;35(x):2081–2088.
   PubMedGoogle Scholar
• Workman CJ, Wang Y, El Kasmi KC, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol. 2009;182(4):1885–1891.
   PubMed Web of Science ®Google Scholar
• Huard B, Mastrangeli R, Prigent P, et al. Characterization of the major histocompatibility complex class II bindin site on LAG-3 protein. Proc Natl Acad Sci USA. 1997;94(11):5744–5749.
   PubMed Web of Science ®Google Scholar
• Huard B, Prigent P, Pages F, et al. T cell major histocompatibility complex calss II molecules down- regulate CD4+ T cell clone responses following LAG-3 binding. Eur J Immunol. 1996;26(5):1180–1186.
   PubMed Web of Science ®Google Scholar
• Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets. 2011;15(1):91–101.
   PubMed Web of Science ®Google Scholar
• Wang Y, Dong T, Xuan Q, et al. Lympgocyte-activation gene-3 expression and prognostic value in neoadjuvant-treated triple negative breast cancer. J Breast Cancer. 2018;21(2):124–133.
   PubMed Web of Science ®Google Scholar
• Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. 2011;186(9):5173–5183.
   PubMed Web of Science ®Google Scholar
• Scurr M, Ladell K, Besneus M, et al. Highly prevalent colorectal cancer-infiltrating LAP+Foxp3− T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunol. 2014;7(2):428–439.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Lambley E, Duraiswamy J, et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006;108(7):2280–2289.
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NYESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 2010;107:7875–7880.
   PubMed Web of Science ®Google Scholar
• Kotaskova J, Tichy B, Trbusek M, et al. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. J Mol Diagn. 2010;12:328–334.
   PubMed Web of Science ®Google Scholar
• Lee KM, Baris D, Zhang Y, et al. Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. Am J Hematol. 2010;85:560–563.
   PubMed Web of Science ®Google Scholar
• Li FJ, Zhang Y, Jin GX, et al. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett. 2013;150:116–122.
   PubMed Web of Science ®Google Scholar
• Takaya S, Saito H, Ikeguchi M. Upregulation of immune checkpoint molecules, PD-1 and LAG-3, on CD4+ and CD8+ T cells after gastric cancer surgery. Yonago Acta Med. 2015;58:39–44.
   PubMed Web of Science ®Google Scholar
• Triebel F, Brignone C. Immutep, France. Combined preparations for the treatment of cancer or infection. United States patent US 2018271940. 2018 Sep 27.
   Google Scholar
• Triebel F. Institut Gustav Roussy, France; Applied Research Systems ARS Holding NV, Netherlands Antilles. Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment. United States patent US 6,410,509. 2002 Jun 25.
   Google Scholar
• Triebel F. Immutep, France. LAG-3Ig (IPM321) dosage regimes for use in the treatment of cancer. European patent EP 2,205,257. 2013 Sep 11.
   Google Scholar
• Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patient with advanced renal cell carcinoma. Clin Cancer Res. 2009;15:6225–6231.
   PubMed Web of Science ®Google Scholar
• Triebel F. Immutep, France. Combined preparations for the treatment of cancer: Unitent States patent US 2016310570. 2016 Oct 27.
   Google Scholar
• Triebel F. Immutep, France. Plurality of doses of recombinant LAG-3 for use in eliciting a monocyte immune response. European patent EP 2,604,275. 2017 Nov 22.
   Google Scholar
• Brignone C, Gutierrez M, Mefti F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med. 2010;8:71.
   PubMed Web of Science ®Google Scholar
• Legat A, Meby-El Hajjami H. Baumgaertner, et al. vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell reponses in metastatic melanoma patients. Reports of a phase I/IIa clinical trial. Clin Cancer Res. 2016;22::1330–1340.
   PubMed Web of Science ®Google Scholar
• Kano Y, Iguchi T, Matsui H, et al. Combined adjuvants of poly (I: C) plus LAG-3Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion. Cancer Sci. 2016;107(4):398–406.
   PubMed Web of Science ®Google Scholar